Suppr超能文献

非酒精性脂肪性肝病的自然史——不断变化的观点。

The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

机构信息

Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 9500 Euclid Avenue, Mail Code A30, Cleveland, OH 44195, USA.

Department of Gastroenterology and Hepatology, Transplantation Center, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 9500 Euclid Avenue, Mail Code A30, Cleveland, OH 44195, USA; Department of Pathobiology, Transplantation Center, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 9500 Euclid Avenue, Mail Code A30, Cleveland, OH 44195, USA.

出版信息

Clin Liver Dis. 2018 Feb;22(1):11-21. doi: 10.1016/j.cld.2017.08.003.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease worldwide, and its clinical and economic burden will continue to grow with parallel increases in rates of obesity, diabetes, and the metabolic syndrome. Evolving understanding of the natural history of NAFLD suggests that these patients are at risk for disease progression to steatohepatitis, fibrosis, and cirrhosis. Recent studies also suggest that these patients are at elevated risk for cardiovascular-, malignancy-, and liver-related morbidity and mortality, although their risk for progression, decompensation, and hepatocellular carcinoma may be less than that of patients with alternative causes of chronic liver disease.

摘要

非酒精性脂肪性肝病(NAFLD)是全球慢性肝病的主要病因,随着肥胖症、糖尿病和代谢综合征发病率的上升,其临床和经济负担将继续增加。对 NAFLD 自然史的认识不断发展表明,这些患者存在疾病进展为脂肪性肝炎、纤维化和肝硬化的风险。最近的研究还表明,这些患者发生心血管疾病、恶性肿瘤和肝脏相关发病率和死亡率的风险增加,尽管与其他原因引起的慢性肝病患者相比,其进展、失代偿和肝细胞癌的风险可能较低。

相似文献

1
The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.
Clin Liver Dis. 2018 Feb;22(1):11-21. doi: 10.1016/j.cld.2017.08.003.
2
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
3
Natural History of Nonalcoholic Fatty Liver Disease.
Dig Dis Sci. 2016 May;61(5):1226-33. doi: 10.1007/s10620-016-4095-4. Epub 2016 Mar 22.
5
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults.
Clin Liver Dis. 2016 May;20(2):313-24. doi: 10.1016/j.cld.2015.10.010. Epub 2015 Dec 24.
7
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pharmacol Rep. 2020 Feb;72(1):1-12. doi: 10.1007/s43440-019-00020-1. Epub 2020 Jan 8.
9
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
10
Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach.
Can J Gastroenterol Hepatol. 2020 Jan 21;2020:9181368. doi: 10.1155/2020/9181368. eCollection 2020.

引用本文的文献

3
Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction-Associated Steatotic Liver Disease in Midlife: The CARDIA Study.
J Am Heart Assoc. 2025 Apr 15;14(8):e037948. doi: 10.1161/JAHA.124.037948. Epub 2025 Apr 7.
5
Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.
Adv Sci (Weinh). 2025 Apr;12(15):e2412903. doi: 10.1002/advs.202412903. Epub 2025 Feb 20.
6
Association between surrogate indices of fatty liver and the risk of colorectal cancer: a cross-sectional United States study.
Transl Cancer Res. 2025 Jan 31;14(1):313-326. doi: 10.21037/tcr-24-1444. Epub 2025 Jan 23.
7
The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014.
Front Endocrinol (Lausanne). 2025 Jan 14;15:1499735. doi: 10.3389/fendo.2024.1499735. eCollection 2024.
8
Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Biomedicines. 2025 Jan 1;13(1):80. doi: 10.3390/biomedicines13010080.
9
Jiangzhi Granule Ameliorates JNK-Mediated Mitochondrial Dysfunction to Reduce Lipotoxic Liver Injury in NASH.
Diabetes Metab Syndr Obes. 2025 Jan 6;18:23-36. doi: 10.2147/DMSO.S492174. eCollection 2025.

本文引用的文献

1
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions.
Dig Liver Dis. 2017 May;49(5):471-483. doi: 10.1016/j.dld.2017.01.147. Epub 2017 Jan 23.
2
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
J Hepatol. 2016 Sep;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013. Epub 2016 May 17.
3
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
Adv Ther. 2016 Mar;33(3):291-319. doi: 10.1007/s12325-016-0306-9. Epub 2016 Feb 26.
6
8
Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.
Pharmacoeconomics. 2015 Dec;33(12):1245-53. doi: 10.1007/s40273-015-0316-5.
10
Nonalcoholic fatty liver disease: a systematic review.
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验